Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome

NCT05873712 is registered in ClinicalTrials.gov with Aseel Alsouqi as lead sponsor.

NCT NCT05873712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05873712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome
Lead sponsor
Aseel Alsouqi
Phase
Phase 2
Overall status
Recruiting
Start date
July 28, 2023
Completion date
December 31, 2026
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent transformed b-cell non-hodgkin lymphoma, recurrent transformed chronic lymphocytic leukemia, recurrent transformed non-hodgkin lymphoma, refractory transformed, refractory transformed b-cell non-hodgkin lymphoma, refractory transformed chronic lymphocytic leukemia, refractory transformed non-hodgkin lymphoma, transformed chronic lymphocytic leukemia to diffuse large b-cell lymphoma